ALPS Advisors’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,154
| Closed | -$344K | – | 1007 |
|
|
2023
Q1 | $344K | Sell |
1,154
-33
| -3% | -$9.85K | ﹤0.01% | 696 |
|
|
2022
Q4 | $408K | Buy |
1,187
+234
| +25% | +$80.4K | ﹤0.01% | 666 |
|
|
2022
Q3 | $180K | Sell |
953
-84
| -8% | -$15.9K | ﹤0.01% | 1009 |
|
|
2022
Q2 | $219K | Sell |
1,037
-760
| -42% | -$161K | ﹤0.01% | 978 |
|
|
2022
Q1 | $601K | Sell |
1,797
-226
| -11% | -$75.6K | 0.01% | 406 |
|
|
2021
Q4 | $658K | Sell |
2,023
-119
| -6% | -$38.7K | 0.01% | 453 |
|
|
2021
Q3 | $1.04M | Buy |
2,142
+115
| +6% | +$55.8K | 0.01% | 384 |
|
|
2021
Q2 | $943K | Sell |
2,027
-728
| -26% | -$339K | 0.01% | 405 |
|
|
2021
Q1 | $1.9M | Buy |
2,755
+20
| +0.7% | +$13.8K | 0.02% | 317 |
|
|
2020
Q4 | $2.02M | Buy |
2,735
+953
| +53% | +$705K | 0.02% | 275 |
|
|
2020
Q3 | $1.24M | Buy |
1,782
+59
| +3% | +$40.9K | 0.02% | 309 |
|
|
2020
Q2 | $1.46M | Buy |
+1,723
| New | +$1.46M | 0.02% | 264 |
|